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Abstract
Background—We tested the hypothesis that states with higher rates of cancers associated with 
human papillomavirus (HPV) would have lower HPV vaccine coverage.
Methods—We gathered state-level data on HPV-related cancer rates and HPV vaccine initiation 
coverage for girls and boys, separately, and HPV vaccine follow-through (i.e., receipt of 3 doses 
among those initiating the series) for girls only. In addition, we gathered state-level data on 
demographic composition and contact with the healthcare system. We calculated Pearson 
correlations for these ecological relationships.
Results—HPV vaccine initiation among girls was lower in states with higher levels of cervical 
cancer incidence and mortality (r=−.29 and −.46, respectively). In addition, vaccine follow-
through among girls was lower in states with higher levels of cervical cancer mortality (r=−.30). 
Other cancer rates were associated with HPV vaccine initiation and follow-through among girls, 
but not among boys. HPV vaccine initiation among girls was lower in states with higher 
proportions of non-Hispanic black residents and lower proportions of higher income residents. 
HPV vaccine follow-through was higher in states with greater levels of adolescents' contact with 
the healthcare system.
Conclusions—HPV vaccine coverage for girls was lower in states with higher HPV-related 
cancer rates. Public health efforts should concentrate on geographic areas with higher cancer rates. 
Strengthening adolescent preventive healthcare use may be particularly important to increase 
vaccine follow-through. Cost-effectiveness analyses may overestimate the benefits of current 
vaccination coverage and underestimate the benefits of increasing coverage.
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National guidelines recommend that 11- and 12-year-old adolescents receive three doses of 
human papillomavirus (HPV) vaccine.1 However, HPV vaccine uptake remains low, with 
coverage levels falling far short of public health goals and uptake of other recommended 
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adolescent vaccines.2,3 In addition, considerable variation in HPV vaccination levels 
between states exists: receipt of all three doses of HPV vaccine ranges from 12.1% of 
adolescent girls in Mississippi to 57.7% of adolescent girls in Rhode Island.3
Preliminary studies demonstrate the effect of HPV vaccination on reducing population levels 
of HPV infection and genital warts,4–6 but the potential impact on cancer outcomes remains 
to be seen. However, examining the relationship between current vaccination patterns and 
cancer rates could foreshadow the future benefits of widespread vaccination. Bach7 
investigated two state characteristics that correlated with levels of HPV vaccine initiation 
among girls (using 2008 vaccination data), highlighting the negative relationship with 
cervical cancer mortality and the positive relationship with median household income. The 
author found that HPV vaccine initiation was more common in states in which girls were at 
lower risk of cervical cancer mortality.
To update and extend these findings and to better understand the ecological pattern of HPV 
vaccination in states across the U.S., we analyzed the relationships between states' HPV 
vaccine coverage and (a) the incidence and mortality rates of HPV-related cancers, (b) 
demographic characteristics, and (c) measures of contact with the healthcare system. We 
hypothesized that states with higher HPV-related cancer rates, including cervical cancer, 
would have lower HPV vaccine coverage.
Materials and Methods
Data sources
We examined data for 50 states and Washington D.C. For the sake of simplicity, we refer to 
all 51 jurisdictions as states hereafter.
Vaccination—Vaccination data came from the 2012 National Immunization Survey-Teen 
(NIS-Teen) (the most recent year of available data at the time of analyses).3 We examined 
HPV vaccine initiation (i.e., received ≥ 1 dose) among adolescents ages 13-17, stratified by 
sex. We examined HPV vaccine follow-through (i.e., received all 3 recommended doses, 
among those who initiated HPV vaccination) only among girls ages 13-17. Follow-through 
differs from three dose completion in that it examines completion only among vaccine 
initiators rather than the entire population; NIS-Teen reports these outcomes separately and 
has noted the different pattern of sociodemographic correlates for initiation and completion 
of three doses versus for follow-through.3 We also gathered data on coverage with tetanus, 
diphtheria, and pertussis booster (Tdap) and meningococcal conjugate vaccine (receipt of 
first dose) for adolescents ages 13-17.
Rates of HPV-related cancer—We obtained incidence and mortality rates per 100,000 
population from the 2001–2010 United States Cancer Statistics database8 for cancers that 
HPV vaccine is currently approved to prevent9,10: anal cancer (both genders) and cervical, 
vaginal, and vulvar cancers (females only). We created a measure of cancer deaths 
attributable to HPV types protected against by the bivalent and quadrivalent HPV vaccines 
(i.e., types 16 and 18).11 Thus, we discounted the annual death rate per 100,000 population 
by the attributable fraction (87% of anal, 76% of cervical, 56% of vaginal, and 44% of 
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vulvar cancer), and then we summed the discounted attributions. Any state with missing data 
on at least one cancer mortality rate (because of fewer than 16 observations during the study 
period) was coded to missing on the summary measure.
Demographics—We used data from the U.S. Census12,13 to examine the racial/ethnic 
composition (2012 data) and median household income (2011–2012 data) of each state. We 
calculated physicians per 100,000 population for three specialties (pediatrics, family 
practice, and obstetrics/gynecology) using data from the Bureau of Labor Statistics14 and 
standardized with population estimates from the U.S. Census.12
Contact with healthcare system—We captured adolescent healthcare adequacy, as 
reported by parents, using two constructs derived from the National Survey of Children's 
Health15: the proportion of adolescents in each state (a) with a medical home and (b) who 
had a healthcare provider whom their parents considered their “personal” doctor or nurse. 
Since around 6% of U.S. schools have health centers that may provide vaccines,16 we used 
data from the School-based Health Alliance17 and the U.S. Census12 to measure the number 
of school-based health centers per 100,000 population in each state.
We calculated the proportion of adult females in each state (ages 18 and older) who had 
received a Pap test in the previous three years using data from the Behavioral Risk Factor 
Surveillance System (BRFSS).18 To account for errors in self-report of Pap testing,19–21 we 
adjusted state-level BRFSS estimates based on the methodology described by Rauscher and 
colleagues.22
Statistical analysis
We examined the relationships between HPV vaccination outcomes and other variables 
using Pearson product-moment correlations yielding r statistics. All statistical tests were 2-
tailed, and we describe in-text all correlations with a p value of < .10 given the ecological 
sample size of k=51 states. We graphed scatterplots for notable relationships. We analyzed 
data using Stata version 13 (College Station, TX).
Results
According to the 2012 NIS-Teen results,3 53.8% of female adolescents had initiated HPV 
vaccine, and 66.7% of those initiators had followed through with receipt of 3 doses of HPV 
vaccine. Among adolescent males, 20.8% had initiated HPV vaccine.
HPV vaccine initiation (girls)
Girls' initiation was lower in states with higher levels of incidence and mortality rates of 
HPV-related cancers: cervical cancer incidence (r=−.29), cervical cancer mortality (r=−.46; 
Figure 1, Panel A), and the summary measure of mortality rates for cancers related to HPV 
16/18 (r=−.58) (Table 1). HPV vaccine initiation among girls was higher in states with 
higher median household incomes (r=.32), lower proportions of non-Hispanic black 
residents (r=−.28), higher proportions of residents of “other” races/ethnicities (r=.24), and 
greater concentrations of pediatricians (r=.47; Figure 1, Panel B) and OB/GYNs (r=.37). 
Initiation among girls was also higher in states with higher levels of other vaccination 
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outcomes: boys' HPV vaccine initiation (r=.43; Figure 1, Panel C), Tdap vaccination (r=.
43), and meningococcal vaccination (r=.48).
HPV vaccine follow-through (girls)
Follow-through was lower in states with higher rates of vaginal cancer incidence (r=−.25), 
cervical cancer mortality (r=−.30), and the summary measure of mortality rates for cancers 
related to HPV 16/18 (r=−.29) (Table 1). Interestingly, follow-through was higher in states 
with higher rates of vulvar cancer incidence (r=.30). In addition, follow-through was higher 
in states with higher levels of other measures of healthcare access: other vaccination 
outcomes (r=.27 to .51), adolescent healthcare adequacy (r=.26 to .37), concentration of 
school health centers (r=.25), and proportion of adult women with a recent Pap test (r=.36; 
Figure 2).
HPV vaccine initiation (boys)
HPV vaccine initiation among boys was higher in states with lower proportions of residents 
that were non-Hispanic white (r=−.31) and higher proportions of residents of “other” races/
ethnicities (r=.32) (Table 1). Boys' initiation was also higher in states with higher levels of 
meningococcal conjugate vaccination (r=.39) and proportions of adolescents with a 
“personal” doctor or nurse (r=.26).
Discussion
In line with our hypothesis, states with higher rates of HPV-related cancers, including 
cervical cancer, had lower HPV vaccine coverage (both initiation and follow-through) 
among girls. Girls' initiation was also associated with demographic composition. However, 
girls' follow-through demonstrated more consistent associations with measures related to 
contact with the healthcare system. For boys, initiation showed some associations with 
demographic composition and contact with the healthcare system, but not HPV-related 
cancer rates. As initiation among boys and girls was highly correlated, it is possible that the 
pattern seen among girls could develop as vaccination among boys becomes more widely 
accepted and coverage increases.
Lower rates of HPV vaccination in areas with higher cancer rates could exacerbate current 
disparities in cancer incidence and mortality across states. One potential mechanism is that 
HPV is sexually transmitted,23 and infections spread through sexual networks that are 
largely geographically bounded.24–26 In addition, HPV vaccine initiation among girls was 
lower in states with a higher proportion of non-Hispanic black residents, an especially 
worrisome finding as black women have among the highest risk for cervical cancer.27 Girls' 
follow-through was associated with lower incidence rates for vaginal cancer and higher 
incidence rates for vulvar cancer, although the reasons for the different directions of these 
relationships is unclear. Promotional efforts should concentrate on increasing HPV 
vaccination, including follow-through, for both boys and girls in areas with high rates of 
HPV-related cancer incidence and mortality. Our findings also suggest that cost-
effectiveness analyses may overestimate the benefits of current vaccination coverage and 
underestimate the benefits of increasing coverage, as girls living in areas with the highest 
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rates of HPV-related cancers were the least likely to initiate the HPV vaccine series. Cost-
effectiveness models should consider the impact of disproportionate vaccination by cancer 
risk on the benefits of vaccine promotional efforts.28–31
Ecological measures of contact with the healthcare system demonstrated consistent, positive 
associations with HPV vaccine follow-through among girls. That is, girls were more likely 
to follow-through with vaccination if they lived in states with greater use of other preventive 
healthcare services. This pattern is not surprising, but it does underscore the need for 
healthcare systems and services that meet the needs of adolescents, who have contact with 
primary care less often than younger children.32 It will be important to test these 
associations with follow-through among boys, as well, but follow-through estimates were 
only available for 11 states in the 2012 NIS-Teen data.3
Some differences emerged between our ecological state-level findings and the individual-
level findings in the report of the 2012 NIS-Teen results.3 HPV vaccine initiation among 
non-Hispanic black girls did not differ from non-Hispanic whites in analyses of individual-
level data, but initiation among girls was higher in states with lower proportions of non-
Hispanic black residents in our ecological analyses. Follow-through was lower among black 
and Hispanic girls than non-Hispanic whites in the individual-level analyses, but no 
relationship between rates of follow-through and demographic composition emerged in our 
ecological analyses. However, for both the individual and ecological analyses, follow-
through was positively associated with white race. Initiation was lower among non-Hispanic 
white boys than other racial/ethnic groups in individual-level analyses, a finding that held 
true in our ecological analyses. Finally, in individual analyses, all vaccination outcomes 
were more common among adolescents living below the federal poverty level than those 
living at or above the poverty level, but we found that median household income was 
positively associated with girls' initiation and no relationship for boys' initiation or girls' 
follow-through. This pattern could reflect multilevel influences on vaccination that vary 
across people and states, including health insurance status and personal beliefs versus public 
health funding and social norms. To the extent that HPV-related cancer rates vary 
systematically by individual race as well as state racial composition, additional research 
should examine the potential causes of these differences in relationships and interventions to 
address them, with an ultimate goal of reducing disparities in vaccination and cancer.
Our analyses have several limitations, including that the findings from the ecological 
analyses we report may not generalize to variability among individuals. The small number 
of observations (n=51) limits the options for statistical analysis of these ecological 
phenomena. Notably, the correlations reported here may vary when controlling for 
additional factors, but adding variables to the models may lead to unstable results. To 
examine the potential impact of controlling for sociodemographic characteristics on the 
relationship between HPV vaccination and cervical cancer mortality, we ran exploratory 
linear regression models that controlled for two state-level variables: median household 
income and demographic composition (percent of residents who are non-Hispanic white, 
non-Hispanic black, and Hispanic). The coefficients of the associations between mortality 
and HPV vaccine initiation and follow-through remained statistically-significant in these 
analyses (p=.04 and p=.02, respectively), increasing our confidence in the findings.
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In addition, we gathered data that were generally cross-sectional. Such data limit our ability 
to make conclusions about causal mechanisms driving vaccine coverage, but they instead 
permitted us to characterize the context in which vaccination took place. Additional studies 
are needed to investigate these causal relationships. Strengths include our use of data from 
high-quality sources, including provider-verified NIS-Teen vaccination data, to get a more 
complete picture of ecological correlations with vaccination than any one data source could 
provide. Our analyses are also among the first to address geographic differences in HPV 
vaccination, an understudied and important topic.
In summary, HPV vaccine coverage in 2012 continued to be correlated with HPV-related 
cancer rates and several other state characteristics. For girls, initiation was associated with 
state-level demographics and cancer rates, while follow-through was related to healthcare 
access. For boys, initiation was associated with state-level demographics and healthcare 
access. Interventions to increase HPV vaccine coverage in areas with high HPV-related 
cancer incidence and mortality rates could result in meaningful public health benefits.
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Association of human papillomavirus (HPV) vaccine initiation rates for girls ages 13-17 and 
(A) cervical cancer mortality per 100,000 women, (B) pediatricians per 100,000 people, and 
(C) HPV vaccine initiation rates for boys ages 13-17.
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Association of human papillomavirus (HPV) vaccine follow-through rates for girls ages 
13-17 and recent Pap testing rates for women ages 18 and older, adjusted for differential 
over-reporting by race.
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Table 1
Correlations of states' demographics, contact with healthcare system, and burden of human papillomavirus 




Burden of HPV-related cancers, 2001–10
Anal cancer incidence (k=50) −0.04 −0.07 0.04
Cervical cancer incidence (k=50) −0.29* −0.19 0.06
Vaginal cancer incidence (k=50) −0.22 −0.25† −0.04
Vulvar cancer incidence (k=50) 0.09 0.30* 0.11
Cervical cancer mortality −0.46* −0.30* −0.11
Sum of HPV 16/18-related cancer mortality rates (k=39) −0.58* −0.29† −0.07
Demographics
Median household income, 2011–12 0.32* 0.07 0.16
Percent population non-Hispanic white 0.01 0.22 −0.31*
Percent population non-Hispanic black −0.28* −0.15 0.05
Percent population Hispanic 0.06 −0.23 0.14
Percent population other race/ethnicity 0.24† 0.04 0.32*
Pediatricians per 100,000 population, 2013 0.47* 0.19 0.23
Family practitioners per 100,000 population, 2013 0.08 0.06 0.15
Obstetricians/gynecologists per 100,000 population, 2013 0.37* 0.08 0.15
Contact with healthcare system
HPV vaccine initiation, among boys 0.47* 0.27† --
Tdap vaccination, boys and girls 0.43* 0.41* 0.13
Meningococcal conjugate vaccination, boys and girls 0.48* 0.51* 0.39*
Adolescents with medical home, 2011–12 0.13 0.26† 0.06
Adolescents with “personal” doctor or nurse, 2011–12 0.19 0.37* 0.26†
School health centers per 100,000 population, 2010–11 0.07 0.25† 0.18
Recent Pap test, adjusted 0.18 0.36* 0.10
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